UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-40312
EQRX, LLC
(SUCCESSOR-BY-MERGER TO EQRX, INC.)
(Exact name of registrant as specified in its charter)
50 Hampshire
Street
Cambridge, Massachusetts 02139
(617) 315-2255
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par
value $0.0001 per share
Warrants to purchase one share of common stock at an exercise price of $11.50
(Title of each class of securities covered by this Form)
None
(Titles of all
other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the
box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
| Rule 12g-4(a)(1) |
|
☒ |
| Rule 12g-4(a)(2) |
|
☐ |
| Rule 12h-3(b)(1)(i) |
|
☒ |
| Rule 12h-3(b)(1)(ii) |
|
☐ |
| Rule 15d-6 |
|
☐ |
| Rule 15d-22(b) |
|
☐ |
Approximate number of holders of record as of the certification or notice date: 1*
| * |
On November 9, 2023, Revolution Medicines, Inc., a Delaware corporation (“Revolution
Medicines”), completed the previously announced acquisition of EQRx, Inc., a Delaware corporation (“EQRx”), pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the “Merger Agreement”), by and among
Revolution Medicines, Equinox Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Revolution Medicines (“Merger Sub I”), Equinox Merger Sub II LLC, a Delaware limited liability company and a direct, wholly
owned subsidiary of Revolution Medicines (“Merger Sub II”), and EQRx. Pursuant to the Merger Agreement, Merger Sub I merged with and into EQRx, with EQRx surviving the First Merger as a wholly owned subsidiary of Revolution Medicines (the
“First Merger”), and following the First Merger, EQRx merged with and into Merger Sub II, with Merger Sub II surviving the Second Merger as a wholly owned subsidiary of Revolution Medicines with the name “EQRx, LLC” (the
“Second Merger”). |
Pursuant to the requirements of the Securities Exchange Act of 1934, EQRx, LLC has caused this
certification/notice to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
EQRX, LLC |
|
|
|
|
|
|
|
(successor by merger to EQRx, Inc.) |
|
|
|
|
| Date: November 20, 2023 |
|
|
|
By: |
|
/s/ Jack Anders |
|
|
|
|
|
|
Name: Jack Anders |
|
|
|
|
|
|
Title: Treasurer & Assistant Secretary |